Herbs (Global Traditional) · Ayurveda
Picrorhiza kurroa
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Picrorhiza kurroa is a Himalayan herb containing bioactive compounds picroside I and kutkoside that support liver function through hepatocyte protection. Clinical research demonstrates significant reduction in liver enzyme levels and bilirubin clearance in viral hepatitis patients.
Picrorhiza kurroa (Kutaki) is a perennial herb native to the Himalayan region, growing at altitudes of 3,000-5,000 meters in India, Nepal, and Tibet. The medicinal rhizomes and roots are typically extracted using hydroalcoholic or ethanolic methods to yield standardized extracts containing iridoid glycosides. The plant is harvested from wild sources and is classified as rare/endangered by the IUCN.
Human clinical evidence includes an RCT in acute viral hepatitis using standardized capsules (picroside I: 2.72-2.88mg, picroside II: 5.50-6.00mg) showing significant enzyme normalization (PMID: 9715310). Additional trials include double-blind studies with 375mg three times daily (n=15) and 750mg three times daily (n=20) showing hepatitis benefits without adverse effects, plus a vitiligo trial (n=30) over 3 months (PMID: 2615440).
Clinical studies used 375-750mg three times daily (1,125-2,250mg/day total) for acute viral hepatitis. Rhizome powder: 300-500mg two to three times daily. Standardized extracts contained 2.72-2.88mg picroside I and 5.50-6.00mg picroside II per capsule. Consult a healthcare provider before starting any new supplement.
Picrorhiza kurroa is a medicinal herb used primarily for its bioactive phytochemical constituents rather than macronutrient content. **Primary Bioactive Compounds (Iridoid Glycosides — collectively termed 'Kutkin', typically 3–6% w/w of dried rhizome):** • Picroside I (4-hydroxy-3-methoxycinnamoyl catalpol): ~1.5–3.0% w/w — major hepatoprotective and anti-inflammatory constituent • Picroside II (vanilloyl catalpol): ~1.0–2.5% w/w — considered the principal marker compound; potent choleretic and hepatoprotective activity • Kutkoside (iridoid glycoside): ~0.5–1.5% w/w — contributes to immunomodulatory and anti-inflammatory properties • Picroside III and Picroside IV: trace to minor concentrations (~0.1–0.5%). **Other Bioactive Constituents:** • Cucurbitacin glycosides (cucurbitacin B, D, and R): trace amounts — contribute to anti-tumor and anti-inflammatory activity • Apocynin (acetovanillone): ~0.05–0.2% w/w — potent NADPH oxidase inhibitor with antioxidant effects; well-characterized pharmacologically • D-mannitol (sugar alcohol): present in small amounts in rhizome • Vanillic acid and related phenolic acids: minor quantities contributing to antioxidant capacity • Androsin (phenolic glycoside): trace amounts. **Micronutrients & Minerals (approximate, per dried rhizome):** • Iron: ~2–5 mg/100g • Calcium: ~50–120 mg/100g • Magnesium: ~30–80 mg/100g • Zinc: ~1–3 mg/100g • Potassium: ~100–250 mg/100g. **Fiber & Macronutrients:** • Crude fiber: ~15–25% of dried rhizome • Crude protein: ~5–8% • Total ash content: ~4–7% • Moisture content (dried): ~8–12%. **Bioavailability Notes:** Picroside II demonstrates moderate oral bioavailability in animal models (~20–30%), with hepatic first-pass metabolism to its aglycone catalpol and vanillic acid. Kutkin (standardized mixture of picroside I and kutkoside, typically 60:40 ratio) shows enhanced absorption when taken with warm water or mild fat-containing vehicles, consistent with traditional Ayurvedic administration (anupana). Apocynin is rapidly absorbed orally with good systemic availability. Standardized extracts (e.g., Picroliv®, standardized to ≥60% kutkin/picroside content) are used in most clinical and pharmacological studies to ensure consistent bioactive delivery. The bitter iridoid glycosides also stimulate gastric acid and bile secretion, which may enhance absorption of co-administered nutrients.
Picrorhiza kurroa's primary bioactives picroside I and kutkoside protect hepatocytes by stabilizing cell membranes and enhancing antioxidant enzyme activity. The compounds suppress pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 through NF-κB pathway inhibition. Additionally, kutkoside stimulates bile acid production and promotes liver regeneration via hepatocyte growth factor activation.
A randomized controlled trial in acute viral hepatitis patients showed picrorhiza extract significantly reduced bilirubin clearance time to 27.44 days compared to 75.9 days with placebo. The study involved 33 patients and demonstrated moderate evidence for hepatoprotective effects. Additional preliminary animal studies support anti-inflammatory mechanisms, though human data for inflammatory conditions remains limited. Current clinical evidence is strongest for liver support applications.
Picrorhiza kurroa appears generally well-tolerated in clinical studies with minimal reported adverse effects. However, it may theoretically interact with hepatically-metabolized medications due to its effects on liver enzyme activity. Individuals with autoimmune conditions should exercise caution as the herb may modulate immune system function. Safety during pregnancy and lactation has not been established, so use should be avoided during these periods.
